Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prazosin for recurrent nightmares in patients with major depressive disorder
ChiCTR-TRC-12002799Phase 3Recruiting
- Sponsor
- NA
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of prazosin in nightmare disorder and major depressive disorder (MDD) (2 arms), sponsored by NA. Primary endpoint: Severity of nightmares. Started Dec 2010; status: recruiting.
02
Drugs
prazosin
03
Conditions
nightmare disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR-TRC-12002799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002799.